Incorporating connectivity into conservation planning for the optimal representation of multiple species and ecosystem services

Funding was provided by the Rainforest Trust foundation. Support was also provided by the Sabah Forest Department, Forest Research Centre, the South East Asia Rainforest Research Partnership, the U.N. Development Programme, the Universiti Malaysia Sabah (FRGS0414-STWN-1/2015), PACOS Trust, BC Initiative, the Natural Environment Research Council UK (grant NE/R009597/1), and the Universities of Aberdeen, Montana, and York. We are grateful to the numerous researchers that collected the data used in our analyses, as well as the local communities and government staff who manage forested areas across Sabah.Peer reviewedPostprin

Conservation assessment and spatial distribution of endemic orchids in Sabah, Borneo

Orchids are among the most threatened plants due to habitat loss and illegal harvesting for horticultural demands. Sabah is a centre of orchid diversity, with approximately 1300 species of which 250 orchid taxa are endemic to Sabah. In this study, we conducted an IUCN Red List assessment on 136 endemic species and used Maximum Entropy (MaxEnt) to develop species distribution models for 47 species. The species distribution models were developed using presence-only data and six environmental predictors. The accuracy of the models were assessed using the area under the curve (AUC) and models with an AUC of higher than 0.8 stacked together to produce a species richness heatmap. We found that 83% of the researched species were threatened, of which 14 species were assessed to be Critically Endangered, eight species as Endangered and 93 species as Vulnerable. The heatmap shows that all of the species occurred within the Totally Protected Area (TPA) network in western Sabah. The heatmap highlighted the mid-altitude areas adjacent to the Kinabalu and Crocker Range parks and Ulu Sipitang regions as areas with a high species richness that were outside the TPA network. These areas are also important for the conservation of the majority of the species assessed as Critically Endangered and Endangered. Urgent conservation actions are needed to protect these species from extinction. The results from this work will be used as part of an intensive conservation action plan for threatened endemic orchids of Sabah and used to identify important plant areas currently not within the existing TPA networ

Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

Abstract Introduction Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-tumour necrosis factor biologic. Safety and efficacy data for CZP over 3 years have been previously reported. We report 3-year quality of life (QoL) outcomes for patients treated with CZP, pooled from two phase 3 trials. Methods Adults with moderate-to-severe plaque psoriasis for ≥ 6 months were initially randomised 1:2:2 to double-blinded placebo every 2 weeks (Q2W), CZP 200 mg Q2W (loading dose of CZP 400 mg at weeks 0/2/4) or CZP 400 mg Q2W. All patients received open-label CZP (200 mg or 400 mg Q2W) from week 48. Dermatology Life Quality Index (DLQI), 36-Item Short Form Survey (SF-36), EuroQol 5-Dimensions 3-Level (EQ-5D-3L) and Work Productivity and Activity Impairment (WPAI) scores are reported as observed. Results At week 0, 100 patients were randomised to placebo, 186 to CZP 200 mg Q2W and 175 to CZP 400 mg Q2W. For CZP-randomised patients, 60.9% had a DLQI score of 0 or 1 by week 48. Both the physical and mental component scores of SF-36 also improved from baseline to week 48 (mean change from baseline: 4.4 and 5.4, respectively). The proportion of patients with a score of 1 in the EQ-5D-3L Pain/Discomfort dimension increased (week 0, 21.1%; week 48, 66.2%), and WPAI Presenteeism, Work Impairment, and Activity Impairment improved from baseline to week 48, with the strongest gains observed for Activity Impairment (week 0, 33.3% of time impaired; week 48, 6.7%). Across patient-reported outcomes, gains were sustained through week 144, with durable improvements observed regardless of sex, psoriatic arthritis status or prior exposure to biologics. Conclusion CZP treatment was associated with sustained and tangible improvements in health-related QoL (DLQI and SF-36), health status (EQ-5D-3L) and functional impairment at work and in other daily activities (WPAI). Trial Registration ClinicalTrials.gov NCT02326298 (CIMPASI-1) and NCT02326272 (CIMPASI-2). Video Abstract (MP4 110310 kb